Is Crinecerfont Capsule in shortage?
Crinecerfont Capsule is listed by FDA as being discontinued by at least one maker (updated Apr 28, 2026).
Every listed package
FDA tracks shortages per package. What each maker reports, most recently updated first:
- Crenessity, Capsule, 25 mg (NDC 70370-5025-1)
Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).
Maker contact: 858-617-7600
Crinecerfont Capsule shortage questions
Is Crinecerfont Capsule in shortage?
Crinecerfont Capsule is listed by FDA as being discontinued by at least one maker (updated Apr 28, 2026).
What should I do if I can’t get Crinecerfont Capsule?
Don’t stop or ration it on your own. Ask your pharmacist whether another strength, package size or maker is in stock, and ask your prescriber about an alternative if none is.
Source: FDA Drug Shortages Database via openFDA. FDA notes that openFDA data is unvalidated and should not be used to make decisions about medical care; ask your pharmacist or prescriber before changing any medication. FDA Drug Shortages Database.